The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)
Deadline: June 12, 2024
5 pm
Amount: NCI will provide up to $100,000 per year toward the salary of the career award recipient plus fringe benefits. NCI will provide up to $50,000 per year toward the research development costs of the award recipient, which must be justified and consistent with the stage of development of the candidate and the proportion of time to be spent in research or career development activities. Indirect Costs are reimbursed at 8% of modified total direct costs.
Purpose
This Notice of Funding Opportunity (NOFO) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.
This NOFO is designed for applicants proposing research in which leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial is optional.
The objective of the NCI Transition Career Development Award (K22) is to provide support to mentored, non-independent investigators in transitioning to their first independent tenure-track faculty cancer research positions, or their equivalent, with an enhanced probability of success for obtaining independent NIH or other research project grant support. Candidates in mentored, non-independent cancer research positions who have had at least 2 years of postdoctoral cancer research training, but, no more than a total of 8 years of mentored, non-independent training experience after the terminal research doctorate or clinical degree may apply, and if selected for funding, must obtain tenure-track faculty, or equivalent, positions before awards will be issued.
The NCI K22 award will provide up to 3 years of support. The K22 award period is intended to enable the investigator to establish a productive independent cancer research program and to generate preliminary data for a subsequent R01 or equivalent grant application submission. NCI believes that the creativity and innovation of new independent cancer research investigators in their early career stages play an integral role in addressing our Nation’s biomedical, behavioral, and clinical cancer research needs.
More Info: https://grants.nih.gov/grants/guide/pa-files/PAR-24-117.html